<p>令一些股東感到惱火的是，<strong>中進醫療</strong>（NASDAQ:ZJYL）在過去一個月的股價下跌了 27%，這延續了該公司的糟糕表現。對於任何長期股東來説，過去一個月結束了一年難以忘懷的經歷，鎖定了 74% 的股價下跌。</p>
<p>儘管價格大幅下跌，但中進醫療目前的市盈率（&#34;P/E&#34;）為 21.8 倍，可能仍在發出看跌信號，因為美國幾乎一半的公司市盈率低於 18 倍，甚至低於 10 倍的市盈率也並不罕見。然而，市盈率可能高是有原因的，需要進一步調查以確定其合理性。</p>
<p>這項技術可能會取代計算機：發現 20 只正在努力使量子計算成為現實的股票。</p>
<p>例如，中進醫療最近盈利的下降值得深思。一個可能性是，市盈率高是因為投資者認為該公司在不久的將來仍會表現優於大盤。你真的希望如此，否則你就是在為沒有特別理由的高價買單。</p>
<p>查看我們對中進醫療的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1763979992664?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1763979992664"/></p>
<p>NasdaqCM:ZJYL 市盈率與行業比較 2025 年 11 月 24 日</p>
<p>儘管沒有中進醫療的分析師預測，但請查看這個 <strong>免費的</strong> 數據豐富的可視化，看看該公司在盈利、收入和現金流方面的表現。</p>
<h2>中進醫療的增長趨勢如何？</h2>
<p>中進醫療的市盈率對於一家預計將實現穩健增長的公司來説是典型的，重要的是，它的表現將優於市場。</p>
<p>首先回顧一下，公司的每股收益增長去年並不令人興奮，出現了 39% 的令人失望的下降。這意味着在長期內，它的盈利也出現了下滑，過去三年每股收益總共下降了 99%。因此，不幸的是，我們必須承認該公司在這段時間內未能有效地增長盈利。</p>
<p>與市場相比，市場預計在未來 12 個月將實現 16% 的增長，而該公司基於最近中期盈利結果的下行勢頭則顯得令人沮喪。</p>
<p>鑑於此，中進醫療的市盈率高於大多數其他公司令人擔憂。顯然，許多投資者對該公司的看法遠比最近的情況更為樂觀，並且不願意以任何價格拋售他們的股票。只有最勇敢的人才會認為這些價格是可持續的，因為最近的盈利趨勢的持續可能會對股價產生重大壓力。</p>
<h2>關鍵要點</h2>
<p>如果説中進醫療的市盈率背後還有一些堅實的力量，儘管最近股價不佳。僅僅依靠市盈率來判斷是否應該出售股票並不明智，但它可以作為公司未來前景的實用指南。</p>
<p>我們已經確定，中進醫療目前的市盈率遠高於預期，因為其最近的盈利在中期內一直在下降。當我們看到盈利下滑並且表現不及市場預期時，我們懷疑股價面臨下跌風險，從而導致高市盈率降低。如果最近的中期盈利趨勢持續下去，將使股東的投資面臨重大風險，並可能使潛在投資者支付過高的溢價。</p>
<p>你應該始終考慮風險。舉個例子，我們發現了 <strong>中進醫療的 4 個警告信號</strong>，你應該注意，其中 1 個不容忽視。</p>
<p>如果這些 <strong>風險讓你重新考慮對中進醫療的看法</strong>，請探索我們的高質量股票互動列表，以瞭解還有什麼其他選擇。</p>

中進醫療

<p>中進醫療國際有限公司（NASDAQ:ZJYL）的股價在過去一個月下跌了 27%，延續了一年來 74% 的下降趨勢。儘管市盈率高達 21.8 倍，但公司的盈利卻在下降，這引發了對未來股價穩定性的擔憂。投資者依然持樂觀態度，但高市盈率暗示如果盈利趨勢持續，可能存在風險。股東應考慮這些風險，並探索其他投資選擇</p>

<p>To the annoyance of some shareholders, <strong>Jin Medical International Ltd.</strong> (NASDAQ:ZJYL) shares are down a considerable 27% in the last month, which continues a horrid run for the company. For any long-term shareholders, the last month ends a year to forget by locking in a 74% share price decline.</p>
<div class="lb-trans"><p>令一些股東感到惱火的是，<strong>中進醫療</strong>（NASDAQ:ZJYL）在過去一個月的股價下跌了 27%，這延續了該公司的糟糕表現。對於任何長期股東來説，過去一個月結束了一年難以忘懷的經歷，鎖定了 74% 的股價下跌。</p>
</div><p>In spite of the heavy fall in price, Jin Medical International may still be sending bearish signals at the moment with its price-to-earnings (or &#34;P/E&#34;) ratio of 21.8x, since almost half of all companies in the United States have P/E ratios under 18x and even P/E's lower than 10x are not unusual. However, the P/E might be high for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>儘管價格大幅下跌，但中進醫療目前的市盈率（&#34;P/E&#34;）為 21.8 倍，可能仍在發出看跌信號，因為美國幾乎一半的公司市盈率低於 18 倍，甚至低於 10 倍的市盈率也並不罕見。然而，市盈率可能高是有原因的，需要進一步調查以確定其合理性。</p>
</div><p>This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.</p>
<div class="lb-trans"><p>這項技術可能會取代計算機：發現 20 只正在努力使量子計算成為現實的股票。</p>
</div><p>For instance, Jin Medical International's receding earnings in recent times would have to be some food for thought. One possibility is that the P/E is high because investors think the company will still do enough to outperform the broader market in the near future. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.</p>
<div class="lb-trans"><p>例如，中進醫療最近盈利的下降值得深思。一個可能性是，市盈率高是因為投資者認為該公司在不久的將來仍會表現優於大盤。你真的希望如此，否則你就是在為沒有特別理由的高價買單。</p>
</div><p>See our latest analysis for Jin Medical International</p>
<div class="lb-trans"><p>查看我們對中進醫療的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1763979992664" alt="" original-src="https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1763979992664"/></p>
<p>NasdaqCM:ZJYL Price to Earnings Ratio vs Industry November 24th 2025</p>
<div class="lb-trans"><p>NasdaqCM:ZJYL 市盈率與行業比較 2025 年 11 月 24 日</p>
</div><p>Although there are no analyst estimates available for Jin Medical International, take a look at this <strong>free</strong> data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.</p>
<div class="lb-trans"><p>儘管沒有中進醫療的分析師預測，但請查看這個 <strong>免費的</strong> 數據豐富的可視化，看看該公司在盈利、收入和現金流方面的表現。</p>
</div><h2>How Is Jin Medical International's Growth Trending?</h2>
<div class="lb-trans"><h2>中進醫療的增長趨勢如何？</h2>
</div><p>Jin Medical International's P/E ratio would be typical for a company that's expected to deliver solid growth, and importantly, perform better than the market.</p>
<div class="lb-trans"><p>中進醫療的市盈率對於一家預計將實現穩健增長的公司來説是典型的，重要的是，它的表現將優於市場。</p>
</div><p>Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 39%. This means it has also seen a slide in earnings over the longer-term as EPS is down 99% in total over the last three years. So unfortunately, we have to acknowledge that the company has not done a great job of growing earnings over that time.</p>
<div class="lb-trans"><p>首先回顧一下，公司的每股收益增長去年並不令人興奮，出現了 39% 的令人失望的下降。這意味着在長期內，它的盈利也出現了下滑，過去三年每股收益總共下降了 99%。因此，不幸的是，我們必須承認該公司在這段時間內未能有效地增長盈利。</p>
</div><p>Comparing that to the market, which is predicted to deliver 16% growth in the next 12 months, the company's downward momentum based on recent medium-term earnings results is a sobering picture.</p>
<div class="lb-trans"><p>與市場相比，市場預計在未來 12 個月將實現 16% 的增長，而該公司基於最近中期盈利結果的下行勢頭則顯得令人沮喪。</p>
</div><p>In light of this, it's alarming that Jin Medical International's P/E sits above the majority of other companies. Apparently many investors in the company are way more bullish than recent times would indicate and aren't willing to let go of their stock at any price. Only the boldest would assume these prices are sustainable as a continuation of recent earnings trends is likely to weigh heavily on the share price eventually.</p>
<div class="lb-trans"><p>鑑於此，中進醫療的市盈率高於大多數其他公司令人擔憂。顯然，許多投資者對該公司的看法遠比最近的情況更為樂觀，並且不願意以任何價格拋售他們的股票。只有最勇敢的人才會認為這些價格是可持續的，因為最近的盈利趨勢的持續可能會對股價產生重大壓力。</p>
</div><h2>The Key Takeaway</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><p>There's still some solid strength behind Jin Medical International's P/E, if not its share price lately. Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.</p>
<div class="lb-trans"><p>如果説中進醫療的市盈率背後還有一些堅實的力量，儘管最近股價不佳。僅僅依靠市盈率來判斷是否應該出售股票並不明智，但它可以作為公司未來前景的實用指南。</p>
</div><p>We've established that Jin Medical International currently trades on a much higher than expected P/E since its recent earnings have been in decline over the medium-term. When we see earnings heading backwards and underperforming the market forecasts, we suspect the share price is at risk of declining, sending the high P/E lower. If recent medium-term earnings trends continue, it will place shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.</p>
<div class="lb-trans"><p>我們已經確定，中進醫療目前的市盈率遠高於預期，因為其最近的盈利在中期內一直在下降。當我們看到盈利下滑並且表現不及市場預期時，我們懷疑股價面臨下跌風險，從而導致高市盈率降低。如果最近的中期盈利趨勢持續下去，將使股東的投資面臨重大風險，並可能使潛在投資者支付過高的溢價。</p>
</div><p>You should always think about risks. Case in point, we've spotted <strong>4 warning signs for Jin Medical International</strong> you should be aware of, and 1 of them shouldn't be ignored.</p>
<div class="lb-trans"><p>你應該始終考慮風險。舉個例子，我們發現了 <strong>中進醫療的 4 個警告信號</strong>，你應該注意，其中 1 個不容忽視。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Jin Medical International</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果這些 <strong>風險讓你重新考慮對中進醫療的看法</strong>，請探索我們的高質量股票互動列表，以瞭解還有什麼其他選擇。</p>
</div>

由於股價遭遇 27% 的重挫，一些中進醫療國際有限公司（NASDAQ:ZJYL）的股東正在尋求退出